StreetAlpha.app
Home › Stocks › IMA

ImageneBio, Inc. (IMA)

$3.90
▲ +21.88%
LAST CLOSE · NOV 17

ImageneBio is a San Diego biopharmaceutical company developing IMG-007, an experimental antibody for autoimmune and inflammatory diseases. It last closed at $3.90 on Nov 17, up 21.88% on the day.

AI Auto Pilots
Is IMA in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$43.3M
EPS (diluted)
−$2.11
Valuation
Market cap
$48.6M
12.5M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$84.9M
At Sep 30
Shareholder equity
$128.1M
Shares outstanding
12.5M
At Oct 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $31.0M$31.0MFY2021FY2022: $15.6M$15.6MFY2022FY2023: $9.2M$9.2MFY2023FY2024: $3.5M$3.5MFY2024FY2025: $800K$800KFY2025

From IMA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Last report
Nov 9
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated IMA in the past 90 days, not enough for a consensus
Average 12-month target
$28.00
▲ 617.9% upside

Based on 1 analyst who set a price target on IMA in the past 90 days. The average target is $28.00, with a high of $28.00 and a low of $28.00, compared with the last close of $3.90.

Low $28.00Avg $28.00High $28.00
Blue marker: last close $3.90
Highest target$28.00
Average target$28.00
Lowest target$28.00
Latest rating changes
HC Wainwright & Co.Initiated
Aug 21Buy$28
DateFirmActionRatingPrice target
Aug 21HC Wainwright & Co.InitiatedBuy$28
Loading…

Technical Analysis

IMA · as of the Nov 17 close · updated after every close
Downtrend

The stock is 1% below its 20 day and 11% below its 50 day average. It is 39% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 48). The nearest support is the swing low (Oct 26) at $3.88, and the nearest resistance the 20 day average at $3.93.

Short trendBearish
Long trendBearish
MomentumFading
StretchNormal
VolatilityNormal, 7.6%/day
Key levels
$8.2552 week high+111.5%
$5.44200 day average+39.5%
$4.99100 day average+27.9%
$4.3350 day average+11.0%
$4.30Swing high (Nov 9)+10.3%
$4.24Pivot R1+8.7%
$3.9320 day average+0.8%
$3.90Last close
$3.88Swing low (Oct 26)−0.5%
$3.62Pivot−7.2%
$3.28Pivot S1−15.9%
$3.0052 week low−23.1%
Indicators
RSI (14)47.75Middle of its rangeNeutral
MACD-0.22Below its signal lineBearish
Stochastic27.6Middle of its rangeNeutral
ADX (14)24.5Weak trend
Williams %R-30.8Oversold below −80, overbought above −20Neutral
CCI (20)-93.2Oversold below −100, overbought above 100Neutral
Rate of change−3.0%Change over 10 sessionsBearish
ATR (14)$0.29Typical daily range, 7.6% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for IMA

What happened before

See how IMA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow IMA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How IMA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in IMA in the last 90 days.

Loading…

See today’s whale options flow across the market →

IMA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲14 buying vs 8 selling
  • ▲Held by funds +6.0 pts
  • ▲Funds holding +2
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding3735+5.7%
In funds' top 10110.0%
Held by funds56.0%50.0%+6.0 pts
New / increased4 / 104 / 9+7.7%
Reduced / sold out6 / 212 / 8−60.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See IMA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IMA is in one of them and how their past IMA trades turned out.

IMA in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered IMA in an article yet. Here's the latest on the wider market.

About ImageneBio

ImageneBio is a biopharmaceutical company based in San Diego, California, that is developing treatments for immunological, autoimmune and inflammatory diseases. Its main candidate, IMG-007, is an experimental antibody that targets the OX40 receptor on activated T cells. The company is still in clinical trials and is first testing the candidate in atopic dermatitis, a common form of eczema, with plans to study other conditions. Its intended patients are people with these diseases, and its treatments would be prescribed by physicians.

Headquarters
San Diego, CA